ArticleDiscover oncology2025
A TARGET database-driven nomogram for pediatric osteosarcoma prognosis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo analyze risk factors for pediatric osteosarcoma and to construct and evaluate a risk prediction model for pediatric osteosarcoma.
methodsWe retrospectively analyzed data from patients diagnosed with osteosarcoma between 2000 and 2013 (n = 129) from the TARGET database. First, independent prognostic factors associated with osteosarcoma-specific death were identified through Cox proportional hazards modeling. Subsequently, using these independent prognostic factors, a nomogram model for osteosarcoma-specific survival was constructed using SPSS 25.0 and R 4.1.1. The discrimination of the model was evaluated using the C-index, predictive ability was validated through receiver operating characteristic curves and area under the curve values, calibration was assessed using calibration curves, and clinical utility was measured by decision curve analysis. Additionally, Kaplan-Meier survival analysis was performed to test the rationality of nomogram grouping.
resultsThe final model included six variables: sex, race, tumor-specific side, tumor-specific region, site of first recurrence, and time of first recurrence. The C-indices of the model for predicting 3-year and 5-year survival rates were 0.802 (95% CI: 0.725-0.880) and 0.787 (95% CI: 0.710-0.864), respectively, indicating good discriminatory ability. Calibration curves showed high consistency between predicted and actual survival probabilities. Decision curve analysis indicated that the model has substantial net benefit across a wide range of mortality risk thresholds. Kaplan-Meier survival analysis showed significant differences in prognosis between high-risk and low-risk groups. The nomogram model constructed in this study can accurately predict 1-year, 3-year, and 5-year survival of pediatric osteosarcoma patients and has high clinical utility.
conclusionThis model not only provides an effective survival prediction tool for patients but also offers important references for optimizing treatment strategies for pediatric osteosarcoma, with the aim of improving survival rates and quality of life for osteosarcoma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.